<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32745521</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-953X</ISSN><JournalIssue CitedMedium="Internet"><Volume>144</Volume><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Neurobiology of disease</Title><ISOAbbreviation>Neurobiol Dis</ISOAbbreviation></Journal><ArticleTitle>Accelerated transsulfuration metabolically defines a discrete subclass of amyotrophic lateral sclerosis patients.</ArticleTitle><Pagination><StartPage>105025</StartPage><MedlinePgn>105025</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nbd.2020.105025</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0969-9961(20)30300-4</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis is a disease characterized by progressive paralysis and death. Most ALS-cases are sporadic (sALS) and patient heterogeneity poses challenges for effective therapies. Applying metabolite profiling on 77-sALS patient-derived-fibroblasts and 43-controls, we found ~25% of sALS cases (termed sALS-1) are characterized by transsulfuration pathway upregulation, where methionine-derived-homocysteine is channeled into cysteine for glutathione synthesis. sALS-1 fibroblasts selectively exhibited a growth defect under oxidative conditions, fully-rescued by N-acetylcysteine (NAC). [U<sup>13</sup>C]-glucose tracing showed transsulfuration pathway activation with accelerated glucose flux into the Krebs cycle. We established a four-metabolite support vector machine model predicting sALS-1 metabotype with 97.5% accuracy. Both sALS-1 metabotype and growth phenotype were validated in an independent cohort of sALS cases. Importantly, plasma metabolite profiling identified a system-wide cysteine metabolism perturbation as a hallmark of sALS-1. Findings reveal that sALS patients can be stratified into distinct metabotypes with differential sensitivity to metabolic stress, providing novel insights for personalized therapy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Qiuying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konrad</LastName><ForeName>Csaba</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandhu</LastName><ForeName>Davinder</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roychoudhury</LastName><ForeName>Dipa</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Agilent Technologies, Santa Clara, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Benjamin I</ForeName><Initials>BI</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Roger R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bredvik</LastName><ForeName>Kirsten</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawamata</LastName><ForeName>Hibiki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calder</LastName><ForeName>Elizabeth L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>The Center for Stem Cell Biology, Sloan-Kettering Institute for Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Studer</LastName><ForeName>Lorenz</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Center for Stem Cell Biology, Sloan-Kettering Institute for Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Agilent Technologies, Santa Clara, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manfredi</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA. Electronic address: gim2004@med.cornell.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>Steven S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA. Electronic address: ssgross@med.cornell.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS062055</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS093872</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Dis</MedlineTA><NlmUniqueID>9500169</NlmUniqueID><ISSNLinking>0969-9961</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>452VLY9402</RegistryNumber><NameOfSubstance UI="D012694">Serine</NameOfSubstance></Chemical><Chemical><RegistryNumber>GAN16C9B8O</RegistryNumber><NameOfSubstance UI="D005978">Glutathione</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>K848JZ4886</RegistryNumber><NameOfSubstance UI="D003545">Cysteine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003545" MajorTopicYN="N">Cysteine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053858" MajorTopicYN="N">Metabolic Networks and Pathways</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055442" MajorTopicYN="Y">Metabolome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055432" MajorTopicYN="N">Metabolomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012694" MajorTopicYN="N">Serine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cysteine</Keyword><Keyword MajorTopicYN="N">Disease stratification</Keyword><Keyword MajorTopicYN="N">Metabolomics</Keyword><Keyword MajorTopicYN="N">Methionine</Keyword><Keyword MajorTopicYN="N">Sporadic amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Stable isotope tracing</Keyword><Keyword MajorTopicYN="N">Transsulfuration</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest Nothing to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32745521</ArticleId><ArticleId IdType="mid">NIHMS1620395</ArticleId><ArticleId IdType="pmc">PMC7491150</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2020.105025</ArticleId><ArticleId IdType="pii">S0969-9961(20)30300-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ackerman HD, Gerhard GS, 2016. Bile Acids in Neurodegenerative Disorders. Front. Aging Neurosci. 8, 263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5118426</ArticleId><ArticleId IdType="pubmed">27920719</ArticleId></ArticleIdList></Reference><Reference><Citation>Albano R, Liu X, Lobner D, 2013. Regulation of system x(c)- in the SOD1-G93A mouse model of ALS. Exp. Neurol. 250, 69&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">24041987</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen SP, Duffy LM, Shaw PJ, Grierson AJ, 2015. Altered age-related changes in bioenergetic properties and mitochondrial morphology in fibroblasts from sporadic amyotrophic lateral sclerosis patients. Neurobiol. Aging 36, 2893&#x2013;2903.</Citation><ArticleIdList><ArticleId IdType="pubmed">26344876</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydin S, Yanar K, Simsek B, Cebe T, Sitar ME, Belce A, Cakatay U, 2018. Galactose-induced aging model in rat testicular tissue. J. Coll. Physicians Surg. Pak. 28, 501&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">29950251</ArticleId></ArticleIdList></Reference><Reference><Citation>Budni J, Garcez ML, Mina F, Bellettini-Santos T, da Silva S, Luz APD, Schiavo GL, Batista-Silva H, Scaini G, Streck EL, Quevedo J, 2017. The oral administration of D-galactose induces abnormalities within the mitochondrial respiratory chain in the brain of rats. Metab. Brain Dis. 32, 811&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">28236040</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A, Moglia C, Lunetta C, Marinou K, Ticozzi N, Ferrante GD, Scialo C, Soraru G, Trojsi F, Conte A, Falzone YM, Tortelli R, Russo M, Chio A, Sansone VA, Mora G, Silani V, Volanti P, Caponnetto C, Querin G, Monsurro MR, Sabatelli M, Riva N, Logroscino G, Messina S, Fini N, Mandrioli J, 2017. Factors predicting survival in ALS: a multicenter Italian study. J. Neurol. 264, 54&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">27778156</ArticleId></ArticleIdList></Reference><Reference><Citation>Canosa A, Pagani M, Cistaro A, Montuschi A, Iazzolino B, Fania P, Cammarosano S, Ilardi A, Moglia C, Calvo A, Chio A, 2016. 18F-FDG-PET correlates of cognitive impairment in ALS. Neurology 86, 44&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">26590270</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Park HC, Goligorsky MS, Chander P, Fischer SM, Gross SS, 2012. Untargeted plasma metabolite profiling reveals the broad systemic consequences of xanthine oxidoreductase inactivation in mice. PLoS One 7, e37149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3377762</ArticleId><ArticleId IdType="pubmed">22723833</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Kirk K, Shurubor YI, Zhao D, Arreguin AJ, Shahi I, Valsecchi F, Primiano G, Calder EL, Carelli V, Denton TT, Beal MF, Gross SS, Manfredi G, D&#x2019;Aurelio M, 2018. Rewiring of glutamine metabolism is a bioenergetic adaptation of human cells with mitochondrial DNA mutations. Cell Metab. 10.1016/j.cmet.2018.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2018.03.002</ArticleId><ArticleId IdType="pmc">PMC5932217</ArticleId><ArticleId IdType="pubmed">29657030</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Calvo A, Bovio G, Canosa A, Bertuzzo D, Galmozzi F, Cugnasco P, Clerico M, De Mercanti S, Bersano E, Cammarosano S, Ilardi A, Manera U, Moglia C, Sideri R, Marinou K, Bottacchi E, Pisano F, Cantello R, Mazzini L, Mora G, 2014. Piemonte, S. Valle d&#x2019;Aosta Register for Amyotrophic Lateral, Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol 71, 1134&#x2013;1142.</Citation><ArticleIdList><ArticleId IdType="pubmed">25048026</ArticleId></ArticleIdList></Reference><Reference><Citation>Cistaro A, Valentini MC, Chio A, Nobili F, Calvo A, Moglia C, Montuschi A, Morbelli S, Salmaso D, Fania P, Carrara G, Pagani M, 2012. Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. Eur. J. Nucl. Med. Mol. Imaging 39, 251&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">22089661</ArticleId></ArticleIdList></Reference><Reference><Citation>Codron P, Cassereau J, Vourc&#x2019;h P, Veyrat-Durebex C, Blasco H, Kane S, Procaccio V, Letournel F, Verny C, Lenaers G, Reynier P, Chevrollier A, 2018. Primary fibroblasts derived from sporadic amyotrophic lateral sclerosis patients do not show ALS cytological lesions. Amyotroph Lateral Scler Frontotemporal Degener 19, 446&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">29382228</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport JC, Preux PM, Magy L, Boirie Y, Vallat JM, Beaufrere B, Couratier P, 2001. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am. J. Clin. Nutr. 74, 328&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">11522556</ArticleId></ArticleIdList></Reference><Reference><Citation>Du ZD, Yu S, Qi Y, Qu TF, He L, Wei W, Liu K, Gong SS, 2019. NADPH oxidase inhibitor apocynin decreases mitochondrial dysfunction and apoptosis in the ventral cochlear nucleus of D-galactose-induced aging model in rats. Neurochem. Int. 124, 31&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">30578839</ArticleId></ArticleIdList></Reference><Reference><Citation>Figuera-Losada M, Thomas AG, Stathis M, Stockwell BR, Rojas C, Slusher BS, 2017. Development of a primary microglia screening assay and its use to characterize inhibition of system xc(&#x2212;) by erastin and its analogs. Biochem Biophys Rep 9, 266&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5614578</ArticleId><ArticleId IdType="pubmed">28956014</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi M, Brown RH Jr., 2017. Genetics of amyotrophic lateral sclerosis. Cold Spring Harb Perspect Med. 10.1101/cshperspect.a024125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a024125</ArticleId><ArticleId IdType="pmc">PMC5932579</ArticleId><ArticleId IdType="pubmed">28270533</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghesquiere B, Wong BW, Kuchnio A, Carmeliet P, 2014. Metabolism of stromal and immune cells in health and disease. Nature 511, 167&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">25008522</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman MH, Seelen M, van Doormaal PT, de Jong SW, de Vries JH, van der Kooi AJ, de Visser M, Schelhaas HJ, van den Berg LH, Veldink JH, 2015. Effect of Presymptomatic body mass index and consumption of fat and alcohol on amyotrophic lateral sclerosis. JAMA Neurol 72, 1155&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pubmed">26280944</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismailoglu I, Chen Q, Popowski M, Yang L, Gross SS, Brivanlou AH, 2014. Huntingtin protein is essential for mitochondrial metabolism, bioenergetics and structure in murine embryonic stem cells. Dev. Biol. 391, 230&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4109978</ArticleId><ArticleId IdType="pubmed">24780625</ArticleId></ArticleIdList></Reference><Reference><Citation>Jesus P, Fayemendy P, Nicol M, Lautrette G, Sourisseau H, Preux PM, Desport JC, Marin B, Couratier P, 2017. Hypermetabolism is a deleterious prognostic factor in patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 10.1111/ene.13468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13468</ArticleId><ArticleId IdType="pubmed">28940704</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamata H, Peixoto P, Konrad C, Palomo G, Bredvik K, Gerges M, Valsecchi F, Petrucelli L, Ravits JM, Starkov A, Manfredi G, 2017. Mutant TDP-43 does not impair mitochondrial bioenergetics in vitro and in vivo. Mol. Neurodegener. 12, 37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5422931</ArticleId><ArticleId IdType="pubmed">28482850</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC, 2011. Amyotrophic lateral sclerosis. Lancet 377, 942&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirk K, Gennings C, Hupf JC, Tadesse S, D&#x2019;Aurelio M, Kawamata H, Valsecchi F, Mitsumoto H, Groups APCS, Manfredi G, 2014. Bioenergetic markers in skin fibroblasts of sporadic amyotrophic lateral sclerosis and progressive lateral sclerosis patients. Ann. Neurol. 76, 620&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4192005</ArticleId><ArticleId IdType="pubmed">25090982</ArticleId></ArticleIdList></Reference><Reference><Citation>Konrad C, Kawamata H, Bredvik KG, Arreguin AJ, Cajamarca SA, Hupf JC, Ravits JM, Miller TM, Maragakis NJ, Hales CM, Glass JD, Gross S, Mitsumoto H, Manfredi G, 2017. Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients. Mol. Neurodegener. 12, 76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5655870</ArticleId><ArticleId IdType="pubmed">29065921</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuffner R, Zach N, Norel R, Hawe J, Schoenfeld D, Wang L, Li G, Fang L, Mackey L, Hardiman O, Cudkowicz M, Sherman A, Ertaylan G, Grosse-Wentrup M, Hothorn T, van Ligtenberg J, Macke JH, Meyer T, Scholkopf B, Tran L, Vaughan R, Stolovitzky G, Leitner ML, 2015. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat. Biotechnol. 33, 51&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">25362243</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton KA, Cudkowicz ME, Brown MV, Alexander D, Caffrey R, Wulff JE, Bowser R, Lawson R, Jaffa M, Milburn MV, Ryals JA, Berry JD, 2012. Biochemical alterations associated with ALS. Amyotroph. Lateral Scler. 13, 110&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">22117131</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton KA, Brown MV, Alexander D, Li Z, Wulff JE, Lawson R, Jaffa M, Milburn MV, Ryals JA, Bowser R, Cudkowicz ME, Berry JD, Northeast ALSC, 2014. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotroph Lateral Scler Frontotemporal Degener 15, 362&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">24984169</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee ZW, Low YL, Huang S, Wang T, Deng LW, 2014. The cystathionine gammalyase/hydrogen sulfide system maintains cellular glutathione status. Biochem. J. 460, 425&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pubmed">24707893</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung KY, Pai YJ, Chen Q, Santos C, Calvani E, Sudiwala S, Savery D, Ralser M, Gross SS, Copp AJ, Greene NDE, 2017. Partitioning of one-carbon units in folate and methionine metabolism is essential for neural tube closure. Cell Rep. 21, 1795&#x2013;1808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5699646</ArticleId><ArticleId IdType="pubmed">29141214</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Rush T, Zapata J, Lobner D, 2009. Beta-N-methylamino-l-alanine induces oxidative stress and glutamate release through action on system xc(&#x2212;). Exp. Neurol. 217, 429&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">19374900</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu SC, 2013. Glutathione synthesis. Biochim. Biophys. Acta 1830, 3143&#x2013;3153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3549305</ArticleId><ArticleId IdType="pubmed">22995213</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B, Couratier P, Arcuti S, Copetti M, Fontana A, Nicol M, Raymondeau M, Logroscino G, Preux PM, 2016. Stratification of ALS patients&#x2019; survival: a population-based study. J. Neurol. 263, 100&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">26518423</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesci P, Zaidi S, Lobsiger CS, Millecamps S, Escartin C, Seilhean D, Sato H, Mallat M, Boillee S, 2015. System xC- is a mediator of microglial function and its deletion slows symptoms in amyotrophic lateral sclerosis mice. Brain 138, 53&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4441079</ArticleId><ArticleId IdType="pubmed">25384799</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Block G, Katz JS, Barohn RJ, Gopalakrishnan V, Cudkowicz M, Zhang JR, McGrath MS, Ludington E, Appel SH, Azhir A, 2015. N.P.I. Phase 2 Trial, Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflamm 2 e100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4396529</ArticleId><ArticleId IdType="pubmed">25884010</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayan M, Seeley KW, Jinwal UK, 2016. Identification of Apo B48 and other novel biomarkers in amyotrophic lateral sclerosis patient fibroblasts. Biomark. Med 10, 453&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">27141953</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel SS, Molnar MZ, Tayek JA, Ix JH, Noori N, Benner D, Heymsfield S, Kopple JD, Kovesdy CP, Kalantar-Zadeh K, 2013. Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature. J. Cachexia. Sarcopenia Muscle 4, 19&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3581614</ArticleId><ArticleId IdType="pubmed">22777757</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman R, Allen SP, Goodall EF, Kramer S, Ponger LL, Heath PR, Milo M, Hollinger HC, Walsh T, Highley JR, Olpin S, McDermott CJ, Shaw PJ, Kirby J, 2015. Gene expression signatures in motor neurone disease fibroblasts reveal dysregulation of metabolism, hypoxia-response and RNA processing functions. Neuropathol. Appl. Neurobiol. 41, 201&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4329387</ArticleId><ArticleId IdType="pubmed">24750211</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson BH, Petrova-Benedict R, Buncic JR, Wallace DC, 1992. Nonviability of cells with oxidative defects in galactose medium: a screening test for affected patient fibroblasts. Biochem Med Metab Biol 48, 122&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">1329873</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn FJ, Ioannides ZA, van Eijk RPA, Heggie S, Thorpe KA, Ceslis A, Heshmat S, Henders AK, Wray NR, van den Berg LH, Henderson RD, McCombe PA, Ngo ST, 2018. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J. Neurol. Neurosurg. Psychiatry 89, 1016&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6166607</ArticleId><ArticleId IdType="pubmed">29706605</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Leigh PN, 2000. Positron emission tomography (PET)&#x2013;its potential to provide surrogate markers in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 1 (Suppl. 2), S17&#x2013;S22.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464936</ArticleId></ArticleIdList></Reference><Reference><Citation>Valbuena GN, Rizzardini M, Cimini S, Siskos AP, Bendotti C, Cantoni L, Keun HC, 2016. Metabolomic analysis reveals increased aerobic glycolysis and amino acid deficit in a cellular model of amyotrophic lateral sclerosis. Mol. Neurobiol. 53, 2222&#x2013;2240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4823370</ArticleId><ArticleId IdType="pubmed">25963727</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Eijkemans MJC, Ferguson TA, Nikolakopoulos S, Veldink JH, van den Berg LH, 2017. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J. Neurol. Neurosurg. Psychiatry. 10.1136/jnnp-2017-317077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317077</ArticleId><ArticleId IdType="pmc">PMC5800333</ArticleId><ArticleId IdType="pubmed">29084868</ArticleId></ArticleIdList></Reference><Reference><Citation>van Klaveren RJ, Demedts M, Nemery B, 1997. Cellular glutathione turnover in vitro, with emphasis on type II pneumocytes. Eur. Respir. J. 10, 1392&#x2013;1400.</Citation><ArticleIdList><ArticleId IdType="pubmed">9192948</ArticleId></ArticleIdList></Reference><Reference><Citation>van Weehaeghe D, Ceccarini J, Willekens SM, de Vocht J, van Damme P, van Laere K, 2017. Is there a glucose metabolic signature of spreading TDP-43 pathology in Amyotrophic Lateral Sclerosis? Q J Nucl Med Mol Imaging. 10.23736/S1824-4785.17.03009-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.23736/S1824-4785.17.03009-6</ArticleId><ArticleId IdType="pubmed">29166751</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, 2017. Hypermetabolism appears to be an adverse prognostic biomarker in amyotrophic lateral sclerosis: a potential for therapeutic intervention? Eur. J. Neurol. 10.1111/ene.13470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13470</ArticleId><ArticleId IdType="pubmed">28940741</ArticleId></ArticleIdList></Reference><Reference><Citation>Weijs PJ, 2011. Hypermetabolism, is it real? The example of amyotrophic lateral sclerosis. J. Am. Diet. Assoc. 111, 1670&#x2013;1673.</Citation><ArticleIdList><ArticleId IdType="pubmed">22027048</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuolikainen A, Jonsson P, Ahnlund M, Antti H, Marklund SL, Moritz T, Forsgren L, Andersen PM, Trupp M, 2016. Multi-platform mass spectrometry analysis of the CSF and plasma metabolomes of rigorously matched amyotrophic lateral sclerosis. Parkinson&#x2019;s disease and control subjects, Mol Biosyst 12, 1287&#x2013;1298.</Citation><ArticleIdList><ArticleId IdType="pubmed">26883206</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss M, Kaddurah-Daouk R, 2000. Creatine and creatinine metabolism. Physiol. Rev. 80, 1107&#x2013;1213.</Citation><ArticleIdList><ArticleId IdType="pubmed">10893433</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, Zhang KY, Kariawasam R, Bax M, Fifita JA, Ooi L, Yerbury JJ, Nicholson GA, Blair IP, 2015. Evaluation of skin fibroblasts from amyotrophic lateral sclerosis patients for the rapid study of pathological features. Neurotox. Res. 28, 138&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">26013250</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>